Результаты поиска

Inflammation in cancer: therapeutic opportunities from new insights.

As one part of the innate immune response to external stimuli, chronic inflammation increases the risk of various cancers, and tumor-promoting inflammation is considered one of the enabling characteristics of cancer development. Recently, there has been growing evidence on the role of anti-inflammation therapy in cancer prevention and treatment. And researchers have already achieved several noteworthy outcomes. In the review, we explored the underlying mechanisms by which inflammation affects the occurrence and development of cancer. The pro- or anti-tumor effects of these inflammatory factors

Совпадение в полном тексте источника
… TNFα antibodies or inhibitors such as infliximab are undergoing phase 2 clinical trials in breast and renal cell cancer [ 270 ]. Chemokine receptor antagonists like bicyclam plerixafor are now in clinical use in non-Hodgkin lymphoma and multiple myeloma [ 271 ]. … For example, anti-TNF treatment (infliximab) enhanced the effects of chemotherapy in colon cancer treatment [ 298 ]. On the other hand, TNF can cause cancer cell death, which makes it a possible cancer therapy. …

Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management.

Multiple myeloma is the second-most common hematologic malignancy in adults worldwide. Despite ongoing advancement in therapeutic modalities, it remains an incurable disease with a 5-year survival rate of approximately 50%. The recent development and introduction of anti-BCMA immunotherapies into clinical practice, including chimeric antigen receptor T-cell (CAR-T) therapies and bispecific antibodies, has radically shifted the treatment paradigm. However, despite the promising potential of these therapies for broader application, frequent and significant adverse effects have been reported, bot

Совпадение в полном тексте источника
… If responses remain poor then tumor necrosis factor (TNF) inhibitors (infliximab, adalimumab, etanercept), JAK-2 inhibitors (ruxolitinib), or other T-cell suppressing therapies such as antithymocyte globulin (ATG), cyclophosphamide (Cy), or cyclosporine may be trialed. …

Drug Repurposing at the Interface of Melanoma Immunotherapy and Autoimmune Disease.

Cancer cells have a remarkable ability to evade recognition and destruction by the immune system. At the same time, cancer has been associated with chronic inflammation, while certain autoimmune diseases predispose to the development of neoplasia. Although cancer immunotherapy has revolutionized antitumor treatment, immune-related toxicities and adverse events detract from the clinical utility of even the most advanced drugs, especially in patients with both, metastatic cancer and pre-existing autoimmune diseases. Here, the combination of multi-omics, data-driven computational approaches with

Совпадение в полном тексте источника
… A major breakthrough in the treatment of AD was the development of anti-TNF antibodies (e.g., infliximab, adalimumab). …

Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology.

The acute and long-lasting side effects of modern multimodal tumour therapy significantly impair quality of life and survival of patients afflicted with malignancies. The key components of this therapy include radiotherapy, conventional chemotherapy, immunotherapy and targeted therapies. In addition to established tumour therapy strategies, up to 30 new therapies are approved each year with only incompletely characterised side effects. This consensus paper discusses the risk factors that contribute to the development of a potentially adverse reaction to tumour therapy and, in addition, defines

Совпадение в полном тексте источника
… Tacrolimus, infliximab or mycophenolate are currently suggested for additional immunosuppressive therapy [ 59 ]. …

Окулярная токсичность целевой терапии и иммунотерапии гематологов.

Целенаправленная терапия и иммунная терапия изменили методы борьбы с гематологическими заболеваниями. Однако эти агенты могут также иметь непреднамеренные окулярные неблагоприятные последствия. Эти токсичные вещества часто недооцениваются, но могут существенно повлиять на качество жизни пациентов и на процесс принятия терапевтических решений. Всеобъемлющее понимание этих последствий имеет важное значение для междисциплинарного управления. В этом обзоре обобщаются имеющиеся в настоящее время данные об окулярной токсичности, связанной с современными целенаправленными и иммунными терапиями, испол

Совпадение в полном тексте источника
… In refractory ocular inflammation, steroid-sparing immunosuppressants (such as infliximab for uveitis, or mycophenolate) have been used. …

Chronic Kidney Disease: Strategies to Retard Progression.

Chronic kidney disease (CKD), defined as the presence of irreversible structural or functional kidney damages, increases the risk of poor outcomes due to its association with multiple complications, including altered mineral metabolism, anemia, metabolic acidosis, and increased cardiovascular events. The mainstay of treatments for CKD lies in the prevention of the development and progression of CKD as well as its complications. Due to the heterogeneous origins and the uncertainty in the pathogenesis of CKD, efficacious therapies for CKD remain challenging. In this review, we focus on the follo

Совпадение в полном тексте источника
… Pirfenidone | TGF-β inhibitor Fresolimumab | Anti-TGF-β monoclonal antibody FG3019 | Anti-CTGF monoclonal antibody Anti-oxidative stress | Bardoxolone methyl | Activating Nrf-2 and inhibiting NF-κB pathway Probucol | Phenolic antioxidant Anti-inflammatory | Adalimumab | Anti-TNF-α monoclonal antibody Infliximab …

A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche.

There is a broad spectrum of diseases labeled as multiple myeloma (MM). This is due not only to the composite prognostic risk factors leading to different clinical outcomes and responses to treatments but also to the composite tumor microenvironment that is involved in a vicious cycle with the MM plasma cells. New therapeutic strategies have improved MM patients' chances of survival. Nevertheless, certain patients' subgroups have a particularly unfavorable prognosis. Biological stratification can be subdivided into patient, disease, or therapy-related factors. Alternatively, the biological sig

Совпадение в полном тексте источника
… Anti-CXCR4 Ab (ulocuplumab) (3) CXCL12 inhibitor (olaptesed pegol) Osteoclasts and osteoblast | (1) Bisphosphonates ∗ (2) Anti-DKK1 Ab (3) Anti-RANKL Ab (denosumab ∗ ) (4) Antisclerostin mAb Cytokine signalling | (1) TGF- β antagonists (sotatercept) (2) TNF- α antagonists (etanercept) (3) Anti-TNF- α Ab (infliximab …

Clinical impact of checkpoint inhibitors as novel cancer therapies.

Immune responses are tightly regulated via signaling through numerous co-stimulatory and co-inhibitory molecules. Exploitation of these immune checkpoint pathways is one of the mechanisms by which tumors evade and/or escape the immune system. A growing understanding of the biology of immune checkpoints and tumor immunology has led to the development of monoclonal antibodies designed to target co-stimulatory and co-inhibitory molecules in order to re-engage the immune system and restore antitumor immune responses. Anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies were among t

Совпадение в полном тексте источника
… mg/kg/day of prednisone), and grade 3 and higher irAEs are generally responsive to high-dose steroids (1–2 mg/kg/day of prednisone or equivalent), although the steroid-refractory patients (reported as 2–8 % of patients) [ 20 , 41 ] may require the use of alternate immunosuppressive agents, such as infliximab …

Defibrotide for Protecting Against and Managing Endothelial Injury in Hematologic Malignancies and COVID-19.

Defibrotide, which is approved for treating hepatic veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS), exhibits pleiotropic anti-inflammatory, anti-thrombotic, and fibrinolytic properties, conferring broad endothelial protective effects. Given these mechanisms, defibrotide has potential utility in various conditions involving endothelial injury or activation. In this review we outline the endothelial-protective mechanisms of defibrotide and comprehensively summarize current evidence supporting its applications in hematologic malignancies, including the prevention and treatment

Совпадение в полном тексте источника
… The recommended management of CRS and ICANS includes anti-cytokine agents such as tocilizumab (IL-6 receptor antagonist), anakinra (IL-1 receptor antagonist), siltuximab (anti-IL-6 mAb), etanercept (TNFα inhibitor), and infliximab (anti-TNFα mAb) [ 150 , 151 ]. …

The 'speck'-tacular oversight of the NLRP3-pyroptosis pathway on gastrointestinal inflammatory diseases and tumorigenesis.

The NLRP3 inflammasome is an intracellular sensor and an essential component of the innate immune system involved in danger recognition. An important hallmark of inflammasome activation is the formation of a single supramolecular punctum, known as a speck, per cell, which is the site where the pro-inflammatory cytokines IL-1β and IL-18 are converted into their bioactive form. Speck also provides the platform for gasdermin D protein activation, whose N-terminus domain perforates the plasma membrane, allowing the release of mature cytokines alongside with a highly inflammatory form of cell death

Совпадение в полном тексте источника
… .: infliximab, adalimumab) [ 39 – 44 ]. Several side effects have been described in patients undergoing those treatments, such as renal toxicity, hemolytic anemia, hepatosplenic T-cell lymphoma insomnia, diarrhea, nausea and vomiting, pancreatitis, bone marrow suppression, lymphoma, fatigue [ 45 ]. …

Targeting strategies for bone diseases: signaling pathways and clinical studies.

Since the proposal of Paul Ehrlich's magic bullet concept over 100 years ago, tremendous advances have occurred in targeted therapy. From the initial selective antibody, antitoxin to targeted drug delivery that emerged in the past decades, more precise therapeutic efficacy is realized in specific pathological sites of clinical diseases. As a highly pyknotic mineralized tissue with lessened blood flow, bone is characterized by a complex remodeling and homeostatic regulation mechanism, which makes drug therapy for skeletal diseases more challenging than other tissues. Bone-targeted therapy has b

Selected Abstracts from the 12th Annual Meeting of the Clinical Immunology Society: 2021 Virtual Annual Meeting: Immune Deficiency and Dysregulation North American Conference.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Infliximab improved his colitis. After several genetic evaluations, at age 21, WES identified a novel pathogenic heterozygous nonsense variant in NFKB1 (c.538C>T, p.Gln180Ter). The same pathogenic variant was found in the proband’s father, paternal aunt, cousin, and deceased paternal uncle. …

Всемирный конгресс по болезням остеопороза, остеоартрита и мускулоскелета 2025).

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Versatility of 14-3-3 proteins and their roles in bone and joint-related diseases.

Bone and joint-related diseases, including osteoarthritis (OA), rheumatoid arthritis (RA), and bone tumors, pose significant health challenges due to their debilitating effects on the musculoskeletal system. 14-3-3 proteins, a family of conserved regulatory molecules, play a critical role in the pathology of these diseases. This review discusses the intricate structure and multifunctionality of 14-3-3 proteins, their regulation of signaling pathways, and their interactions with other proteins. We underscore the significance of 14-3-3 proteins in the regulation of osteoblasts, osteoclasts, chon

Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review).

Monoclonal antibody technology plays a vital role in biomedical and immunotherapy, which greatly promotes the study of the structure and function of genes and proteins. To date, monoclonal antibodies have gone through four stages: murine monoclonal antibody, chimeric monoclonal antibody, humanised monoclonal antibody and fully human monoclonal antibody; thousands of monoclonal antibodies have been used in the fields of biology and medicine, playing a special role in the pathogenesis, diagnosis and treatment of disease. In this review, we compare the advantages and disadvantages of hybridoma te

Совпадение в полном тексте источника
… For example, infliximab is capable of preventing and reducing inflammation as the chimeric mAb to tumour necrosis factor (TNF)-α in the treatment of rheumatoid arthritis (RA) and Crohn.s disease ( 47 ). …

Оптимальный выбор способа управления лекарствами в отношении внутримышечной и подкожной инъекции.

Внутримышечное (IV), внутримышечное (IM) и подкожное (SC) three - наиболее часто используемые пути инъекции для лечения лекарств. Время от времени проводились сравнительные исследования СК по отношению к IV, IM по отношению к IV, или IM по сравнению с СК, и некоторые новые выводы совершенно отличаются от рекомендаций в отношении дозировки, описанных в предписаниях в отношении информации. Однако врачи, возможно, до сих пор не знают о таких новых фактах при выборе методов лечения. Поиск литературы MetodsA был проведен с использованием PubMed, MedLINE и Web of Sciences TM Core Collection для анал

Совпадение в полном тексте источника
… Anti-TNF medications include monoclonal antibodies (eg, infliximab, adalimumab, certolizumab pegol, and golimumab) and circulating receptor fusion protein such as etanercept. …

Gut microbiota shapes cancer immunotherapy responses.

The gut microbiota significantly influences cancer immunotherapy efficacy by modulating immune responses, remodeling the tumor microenvironment (TME), and producing key metabolites. Strategies such as FMT, probiotics, and dietary interventions show promise in enhancing responses to ICIs and ACTs while reducing immune-related adverse events (irAEs). This review summarizes clinical and preclinical findings and discusses microbiota-based interventions and future directions for precision immunotherapy.

Совпадение в полном тексте источника
… tumor progression 268 II ( NCT04116775 ) 32 Prostate cancer αPD-1 mAb and hormone therapy Efficacy 269 I ( NCT04883762 ) 4 Solid tumors ICI AEs 270 I/II ( NCT04521075 ) 42 Solid tumors αPD-1 mAb AEs, ORR 271 II ( NCT05286294 ) 20 Solid tumors ICI Safety, ORR 272 I/II ( NCT03819296 ) 800 Solid tumors Infliximab … Prostate cancer | αPD-1 mAb and hormone therapy | Efficacy | 269 I ( NCT04883762 ) | 4 | Solid tumors | ICI | AEs | 270 I/II ( NCT04521075 ) | 42 | Solid tumors | αPD-1 mAb | AEs, ORR | 271 II ( NCT05286294 ) | 20 | Solid tumors | ICI | Safety, ORR | 272 I/II ( NCT03819296 ) | 800 | Solid tumors | Infliximab …

A guide to cancer immunotherapy: from T cell basic science to clinical practice.

The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a central focus for engaging the immune system in the fight against cancer. Basic science discoveries elucidating the molecular and cellular biology of the T cell have led to new strategies in this fight, including checkpoint blockade, adoptive cellular therapy and cancer vaccinology. This area of immunological research has been highly active for the past 50 years and is now enjoying unprecedented bench-to-bedside clinical success. Here, we provide a comprehensive historical and biological perspective regar

Совпадение в полном тексте источника
… Infliximab and other immunosuppressive agents can be used when glucocorticoids fail. Life-threatening (grade 4) toxicities necessitate the complete discontinuation of therapy and the use of life-saving measures, as required. …

Analyzing the impact of subcutaneous injection needle, device, and administration characteristics on patient pain, anxiety, and safety: a systematic literature review.

The subcutaneous (SC) injection route is a commonly used and important method for therapeutic delivery of a wide range of compounds, and needle characteristics have a significant influence on patient pain, anxiety, safety, and other outcomes. This systematic review evaluates the evidence on how needle-specific characteristics (e.g. gauge, length, tip design, wall thickness, concealment) and administration- or device-related factors can affect patient-reported outcomes and clinical safety indicators during and following SC injections. A comprehensive search was conducted in MEDLINE, PubMed, Emb

Sodium-glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond.

Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new drug class initially designed and approved for treatment of diabetes mellitus, have been shown to exert pleiotropic metabolic and direct cardioprotective and nephroprotective effects that extend beyond their glucose-lowering action. These properties prompted their use in two frequently intertwined conditions, heart failure and chronic kidney disease. Their unique mechanism of action makes SGLT2i an attractive option also to lower the rate of cardiac events and improve overall survival of oncological patients with preexisting cardiovascu

Совпадение в полном тексте источника
… Immunosuppressive therapy (if myocarditis or pericardial disease: First line: High-dose corticosteroids (1–2 mg prednisone/kg/day, oral or IV depending on symptoms Methylprednisolone 1 g every day (fulminant myocarditis) Glucocorticoid-refractory and glucocorticoid-resistant: Addition of either mycophenolate, infliximab …